Tetraphase Pharmaceuticals to Host First Quarter 2019 Financial Results Conference Call
May 01 2019 - 7:03AM
Business Wire
Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a
biopharmaceutical company focused on developing and commercializing
novel tetracyclines to treat serious and life-threatening
conditions, today announced that company management will host a
conference call at 4:30 p.m. ET on Wednesday, May 8, 2019 to
discuss the Company’s first quarter 2019 financial results and
provide a general corporate update.
The conference call may be accessed by dialing 844-831-4023
(U.S. and Canada) or 731-256-5215 (international) and entering
conference ID number 2794213. A live audio webcast of the
conference call will be available online from the “Investors –
Events & Presentations” section of the Tetraphase website at
www.tphase.com.
A replay of the conference call will be available from 7:30 p.m.
ET on Wednesday, May 8, 2019, through 7:30 p.m. ET on Wednesday,
May 15, 2019 by dialing 855-859-2056 (U.S. and Canada) and
404-537-3406 for (international) callers. The conference ID number
is 2794213. A replay of the webcast will be available by visiting
Tetraphase’s website.
About Tetraphase Pharmaceuticals, Inc.
Tetraphase Pharmaceuticals, Inc., is a biopharmaceutical company
using its proprietary chemistry technology to create novel
tetracyclines for serious and life-threatening conditions,
including infections caused by many of the multidrug-resistant
bacteria highlighted as urgent public health threats by the World
Health Organization and the Centers for Disease Control and
Prevention. The Company has created more than 3,000 novel
tetracycline compounds using its proprietary technology platform.
Tetraphase's lead product, XERAVA™, is approved for the treatment
of complicated intra-abdominal infections by the U.S. Food and Drug
Administration and the European Medicines Agency. The Company’s
pipeline also includes TP-271 and TP-6076, which are in Phase 1
clinical trials, and TP-2846, which is in preclinical testing for
acute myeloid leukemia. Please visit www.tphase.com for more
company information.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190501005132/en/
Jennifer Vierajviera@tphase.com617-600-7040
Tetraphase Pharmaceuticals (NASDAQ:TTPH)
Historical Stock Chart
From Mar 2024 to Apr 2024
Tetraphase Pharmaceuticals (NASDAQ:TTPH)
Historical Stock Chart
From Apr 2023 to Apr 2024